Guidelines from European Society for Medical Oncology (ESMO)and ASCO published in July 2016 and February 2017, respectively, acknowledge theprognostic value of BRAF V600E mutations; however, they statedthat there was insufficient evidence to conclude that patients withBRAF-mutated CRC do not benefit from anti-EGFR therapies,and therefore should not be used as a predictive biomarker8,9 (Table 3). This evidence concerns the gene BRAF and colorectal carcinoma.